We continually strive to assist you in reaching and maintaining bone health to help prevent future fractures. If you are older than 50 and have had a fracture, or if your orthopaedic specialist feels you will benefit from a bone health evaluation, our Fracture Liaison Service will contact you. This booklet will serve as a guide to help you understand more about osteoporosis and minimizing the risk of another fragility fracture and provide you basic information about maintaining bone health.
Your active participation and positive attitude will help you reach your goals. At no time does this information replace your provider's advice and orders. If you have questions, please call your provider.
Please bring this booklet to all your DMG appointments.
initial visit
During your first visit, we will review your medical history, history of recent fractures, evaluate you for another fracture and discuss treatment options.
questions you may be asked:
-Have you had a bone density test (DEXA) follow-up visits
You will be scheduled for a follow-up one to three months after your initial visit. At that time, your provider will help evaluate your treatment and continue the planning process for your care. 
helpful links

Hospital & Doctor Bills
The services provided by the Fracture Liaison Service are considered a medical necessity by most insurance providers due to the risk of future fractures. Insurance generally covers these expenses. If you are uncertain, please contact your insurance provider to confirm which services are covered.
Health Insurance
If you do receive a bill, be sure to contact your insurance provider to have that portion paid first. Some insurers provide 100 percent of coverage for these preventive services.
Patient Responsibility
Deductibles, co-insurance, copays and other balances are due at the time of service.
Payment Options
Credit antiresorptive medications (Slow bone loss)
Bisphosphonates, calcitonin, denosumab, estrogen and estrogen agonists/ antagonists are antiresorptive medicines. Because your bones are continually losing old tissue and replacing it with new tissue, these medications can help decrease the bone loss that occurs. The goal for patients is to slow bone loss and continue to make new bone at the same pace. These treatments can often help prevent worsening bone loss and will reduce the risk of fracture.
anabolic drugs (Increase the rate of bone formation)
Anabolic drugs increase the rate of bone formation. They are in a distinct category of osteoporosis medicines called anabolic drugs. Currently, Teriparatide (a form of parathyroid hormone) is the only osteoporosis medicine approved by the FDA that rebuilds bone. There are other similar medications being researched, but currently not available for treatment. The goal of treatment with anabolic medication is to build a healthy "bone bank account" and reduce the risk of breaking bones.
Please review the attached list of medications from the National Osteoporosis Foundation for more details. 
laboratory tests
Some lab tests are specific to bone health. Your medical records will be checked to determine testing performed in the previous six months. Lab work may need to be performed based on your history.
x-rays
An X-ray can help your provider determine if you have had any fragility fractures of the spine. The most common result of having osteoporosis is a fragility fracture. More than 1.5 million people suffer a fragility fracture each year. The severity of the fracture depends on where it is located, with the most common locations being the wrist, spine and hip.
spinal curvature
Even if a fracture does not occur, the spinal bones (vertebrae) can become weak and crush together, called a compression fracture. As this happens, the spine curves, which can result in back pain, height loss and difficulty breathing due to less space under the ribs. In addition to these movements, many exercises and activities such as yoga, Pilates, tennis and golf may need to be avoided or adjusted because they often involve twisting and bending motions. Bending forward during routine activities also puts stress on the spine and can increase the chance of breaking a bone in the spine. Since bending forward puts more strain on the spine, it's safer if you're able to keep your back flat. 
loss of mobility
Treatment of osteoporosis in men.
Treatment of glucocorticoid-induced osteoporosis in men and women as a result of long-term use of steroid medicines (such as prednisone and cortisone).
Alendronate reduces bone loss, increases bone density and reduces the risk of fractures in the spine, hip and other bones.
Alendronate is taken daily as a 5 mg or 10 mg tablet, or once weekly as a 70 mg tablet. Aldendronate is taken first thing in the morning after waking up and on an empty stomach. It needs to be swallowed whole with 6-8 ounces of plain water (no other liquid), at least 30 minutes before having anything to eat or drink. Patients must remain upright (sitting, standing or walking) during this 30-minute period. 
Treatment of osteoporosis in men.
Prevention and treatment of glucocorticoid-induced osteoporosis in men and women as a result of long-tern use of steroid medicines (such as prednisone and cortisone).
Risedronate reduces bone loss, increases bone density and reduces fractures in the hip, spine and other bones. Risedronate is taken daily as a 5 mg tablet, weekly as a 35 mg tablet, twice monthly as a 75 mg tablet (on two consecutive days) or monthly as a 150 mg tablet.
Risedronate (Actonel ® ) tablets needs to be taken first thing in the morning after waking up and on an empty stomach. It needs to be swallowed whole with 6-8 ounces of water (no other liquid or additives), at least 30 minutes before having anything to eat or drink. Patients must remain upright (sitting, standing or walking) during this 30-minutes period. For the individuals taking Risedronate with calcium, the calcium must be taken at a different time of the day from the Risedronate tablet and with a meal or a snack.
The Risedronate (Atelvia ® ) delayed-release tablet needs to be taken immediately after breakfast with at least 4 ounces of plain water (no other liquid). 
Prevention and treatment of osteoporosis in men and women as a result of long-term use of steroid medications (such as prednisone and cortisone).
Zoledronic acid reduces bone loss, increases bone density and reduces fractures in the hip, spine and other bones. Studies show that zoledronic acid reduced the risk of new fractures in people who recently broke bones in the hip due to osteoporosis.
Zoledronic acid is given once a year as an IV infusion of 5 mg to treat osteoporosis or every two years as an IV infusion of 5 mg to prevent osteoporosis.
A healthcare professional gives zoledronic acid as an intravenous (IV) infusion in a doctor's office or other outpatient setting.
Patients need to have blood tests before each dose to establish a baseline, including creatinine, to confirm that kidney function is normal and that the blood calcium level is normal.
side effects of bisphosphonate medicines
Side effects for all bisphosphonate medicines may include bone, joint or muscle pain. Side effects of oral tablets may include nausea, difficulty swallowing, heartburn irritation of the esophagus and gastric ulcer. Shortly after receiving an IV bisphosphonate, some patients have flu-like symptoms, fever, headache and pain in muscles or joints. These generally stop within two or three days and usually do not happen with future infusions.
In rare cases, inflammation of the eye (uveitis) may occur. There have also been reports of osteonecrosis (death of bone cells or tissue) of the jaw (ONJ) in patients taking bisphosphonate.
The risk of ONJ in people taking bisphosphonates for osteoporosis is minimal and is increased if you have poor dental hygiene, or have had external radiation to your jaw. In most cases, the benefit of the medication far outweighs any small risk of ONJ. Patients should practice good dental care and work closely with a doctor and dentist to reduce the risk of ONJ.
An unusual fracture of the upper femur (thigh bone) has been associated with bisphosphonates, however this is also very rare. The risk of this complication can be minimized by taking a "holiday" from bisphosphonate medications after 5 to 7 years of use. Tell your healthcare provider if you have been taking bisphosphonates for several years or longer and have an unusual ache or pain in your thigh bone. Some people have a dull ache or pain in the thigh or groin area, sometimes for several weeks or longer, before having an unusual break in the thigh. Patients taking oral bisphosphonate tablets should stop taking the drug and contact their healthcare provider immediately when experiencing chest pain, new or worsening heartburn, or difficult or painful swallowing. It is important that patients report these or other side effects to their healthcare provider.
Bisphosphonates are not recommended for people who have severe kidney disease or low blood calcium. People with certain problems of the esophagus may not be able to take the oral tablets.
antiresorptive medicine: calcitonin
Calcitonin-Salmon (brand names Fortical ® and Miacalcin ® ). Calcitonin medicine is a synthetic hormone for the treatment of osteoporosis in postmenopausal women who are at least five years beyond menopause. Calcitonin is also a naturally occurring hormone in the body that is involved in calcium regulation and bone metabolism.
Calcitonin medicines slow bone loss, increase bone density in the spine and reduce the risk of fractures in the spine. Calcitonin is available as a nasal spray (200 IU daily) or an injection (dosage varies). Due to concerns about increased cancer risk, and the fact that there are more effective medications available for bone loss, calcitonin is not used as a first line medication and is limited to no more than 6 months. 
possible side effects of denosumab medicine
It is important to understand that if your doctor recommends taking Prolia, then the risks of side effects are strongly outweighed by the benefits it provides in preventing fractures. Denosumab may lower calcium levels in the blood. If blood calcium levels are low before receiving denosumab, the low calcium level must be corrected before giving the medicine or it will get worse. Signs of low calcium levels include spasms, twitches or cramps; or numbness and tingling in the fingers, toes or around the mouth.
Patients should report any of these symptoms to their healthcare provider. Most patients with low calcium levels, however, do not show these signs. People who have weak immune systems or take other medicines that affect the immune system may have an increased chance of having serious infections with denosumab. Even patients who have no immune system problems may be at higher risk of certain infections such as those of the skin.
Patients should contact their healthcare provider right away if signs of infection or abnormal skin-related symptoms occur. Infection signs may include fever, chills, red and swollen skin, skin that is hot or sore to the touch, severe pains in the abdomen, or pain or burning when passing urine or passing urine more frequently and in small amounts. Denosumab may also cause skin rashes.
Other side effects can include pain in the back, arms and legs. ONJ and unusual fractures of the upper femur (thigh bone) have been seen in patients taking denosumab (refer to "side effects of bisphosphonate medicines" for additional details about ONJ and unusual femoral fractures). With anabolic medicine (Teriparatide) the goal of treatment is to rebuild bone, increase bone mass, repair microscopic defects in bone and reduce the risk of fractures. A patient's response to treatment is favorable when bone quality and bone density improve and no broken bones occur.
monitoring treatment & length of treatment
A bone density test (DEXA) should be repeated every two years to monitor the effectiveness of treatment with an osteoporosis medicine. Some patients may need to repeat a bone density test after one year. Some healthcare providers may also perform lab tests called biochemical markers of bone turnover tests to learn more about your response to a medicine. At this time, there is no easy way to measure bone quality.
There are currently no conclusive research findings to suggest how long most osteoporosis drugs remain safe and effective, except for Teriparatide (Forteo®). Teriparatide can be taken for no more than two years according to the FDA. After patients stop taking a bisphosphonate medicine, they may continue to experience some of the drug's benefits for several years or even longer.
Other osteoporosis medicines like Deonosumab and Teriparatide stop working quickly which can lead to rapid bone loss in some patients when these medicines are stopped. Patients who have responded well to taking bisphosphonate medicines and are considered at low risk of fracture may be able to discontinue taking these medications after three to five years.
During this break from treatment, it's important to work closely with a healthcare provider to monitor bone health and re-evaluate the need to restart an osteoporosis medicine each year.
People who are considered at high risk for breaking a bone usually need to continue treatment with a bisphosphonate or another osteoporosis medicine to prevent fractures.There is no uniform recommendation that applies to all patients taking osteoporosis medicines. In the absence of clinical studies on duration of treatment, healthcare providers and patients should discuss options to determine the best course of action.
The National Osteoporosis Foundation (NOF) encourages all healthcare providers to evaluate a patient on the basis of clinical risk factors, such as the presence or absence of broken bones, height loss, bone density, age, weight and other factors that affect fracture risk.
Length of treatment should be individualized and based on the person's medical and fracture history, as well as the initial and most recent bone density test results.
adverse events & drug company information
When a patient has a serious reaction or problem with a drug, either the patient or the patient's healthcare provider should report the problem to the FDA. This can be done by calling 1 (800) 332-1088 or completing an online report at www.fda.gov/medwatch. Patients can also notify the pharmaceutical manufacturer. The information below provides the phone numbers of the pharmaceutical manufacturers and the date each medicine was approved by the FDA as an oeteoporosis medicine. 
*Generic versions of these drugs
